Imagine a scenario where a cancer patient undergoes the relentless routine of systemic, hospital-based chemotherapy. Each session involves the painstaking search for a viable vein, often leading to discomfort and the eventual "burning" or damaging of veins, necessitating the search for new injection sites for subsequent treatments. This ordeal is not only physically draining for the patient but also emotionally taxing for caregivers who must juggle their responsibilities to accompany their loved ones, often taking time off work and enduring the emotional weight of the treatment's physical toll on the patient. The side effects of systemic therapies---nausea, fatigue, hair loss, and increased risk of infection---further compound the patient's suffering, affecting their quality of life and well-being. The burden extends beyond the patient and their caregivers, exerting pressure on the healthcare system and government resources. Hospitals are swamped with the logistical challenges of administering these treatments, managing the side effects, and addressing the complications that arise from such invasive procedures. The cost of cancer in the UK is projected to escalate from £78 billion in 2023 to £1.26 trillion by 2040, highlighting the growing financial strain on healthcare systems and the urgency for more efficient treatment modalities. Enter InhaleGen's revolutionary inhalation therapy, poised to dramatically alter this landscape. By enabling patients to self-administer their treatment through inhalation at home, it eliminates the need for invasive needle injections, thereby preserving the patient's veins and significantly reducing the physical discomfort associated with traditional chemotherapy. This approach not only alleviates the strain on patients and their caregivers by removing the need for frequent hospital visits but also significantly reduces the load on healthcare facilities, freeing up resources for other critical needs. Moreover, by minimizing systemic exposure to the drugs, our therapy aims to lessen the severe side effects commonly associated with cancer treatments, improving patients' overall quality of life. This shift towards a more patient-friendly, home-based treatment model promises to relieve the healthcare system and government of some of the heavy burdens associated with cancer care, offering a more sustainable, effective, and compassionate approach to treating one of the most challenging diseases of our time. The global economic cost of cancers from 2020 to 2050, estimated at $25.2 trillion, underscores the critical need for innovative solutions like ours to mitigate the economic and human toll of cancer worldwide.